{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:27:10Z","timestamp":1789986430677,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00262-021-03114-z","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T15:03:11Z","timestamp":1637852591000},"page":"1719-1731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Discontinuation of immune checkpoint inhibitor (ICI) above 18\u00a0months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6811-0941","authenticated-orcid":false,"given":"Geoffroy","family":"Bilger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Doubre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Giaj","family":"Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Ange","family":"Massiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"3","key":"3114_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.21037\/tlcr.2018.05.06","volume":"7","author":"PM Groot","year":"2018","unstructured":"Groot PM, de Wu CC, Carter BW et al (2018) The epidemiology of lung cancer. Transl Lung Cancer Res 7(3):220\u2013233","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3114_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics. CA Cancer J Clin 71(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"3114_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"2","key":"3114_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"10027","key":"3114_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550","journal-title":"Lancet"},{"issue":"10066","key":"3114_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265","journal-title":"Lancet"},{"issue":"19","key":"3114_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"10183","key":"3114_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 393(10183):1819\u20131830","journal-title":"The Lancet"},{"issue":"22","key":"3114_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092","journal-title":"N Engl J Med"},{"issue":"21","key":"3114_CR10","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040\u20132051","journal-title":"N Engl J Med"},{"issue":"24","key":"3114_CR11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"issue":"17","key":"3114_CR12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36(17):1675\u20131684","journal-title":"J Clin Oncol"},{"issue":"28","key":"3114_CR13","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518\u20132527","journal-title":"J Clin Oncol"},{"key":"3114_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S2213-2600(18)30500-9","volume":"4","author":"NB Leighl","year":"2019","unstructured":"Leighl NB, Hellmann MD, Hui R et al (2019) Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 4:347\u2013357","journal-title":"Lancet Respir Med"},{"issue":"Suppl_4","key":"3114_CR15","first-page":"S1142","volume":"31","author":"JR Brahmer","year":"2020","unstructured":"Brahmer JR, Rodriguez-Abreu D, Robinson AG et al (2020) KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \u2265 50%. Annals of Oncol 31(Suppl_4):S1142\u2013S1215","journal-title":"Annals of Oncol"},{"issue":"14","key":"3114_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1200\/JCO.19.02446","volume":"38","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Garon EB, Kim D-W et al (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the Keynote-010 study. J Clin Oncol 38(14):1580\u20131590","journal-title":"J Clin Oncol"},{"issue":"33","key":"3114_CR17","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J et al (2020) Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153. J Clin Oncol 38(33):3863\u20133873","journal-title":"J Clin Oncol"},{"issue":"3","key":"3114_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00262-019-02310-2","volume":"68","author":"E Nadal","year":"2019","unstructured":"Nadal E, Massuti B, D\u00f3mine M et al (2019) Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 68(3):341\u2013352","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3114_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1078155219867131","volume":"26","author":"M Yilmaz","year":"2020","unstructured":"Yilmaz M, Guven MS (2020) Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients. J Oncol Pharm Pract 26(3):761\u2013767","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"3114_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","volume":"39","author":"H Kimura","year":"2019","unstructured":"Kimura H, Araya T, Yoneda T et al (2019) Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond) 39(1):1\u20135","journal-title":"Cancer Commun (Lond)"},{"key":"3114_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378","journal-title":"JAMA Oncol"},{"issue":"2","key":"3114_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479\u2013485","journal-title":"J Cancer Res Clin Oncol"},{"key":"3114_CR23","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/annonc\/mdx414","volume":"28","author":"CE McCoach","year":"2017","unstructured":"McCoach CE, Blumenthal GM, Zhang L et al (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707\u20132714","journal-title":"Ann Oncol"},{"issue":"10","key":"3114_CR24","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"AC Tan","year":"2018","unstructured":"Tan AC, Emmett L, Lo S et al (2018) FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 29(10):2115\u20132120","journal-title":"Ann Oncol"},{"key":"3114_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/pcmr.12503","volume":"29","author":"BY Kong","year":"2016","unstructured":"Kong BY, Menzies AM, Saunders CA et al (2016) Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res 29:572\u2013577","journal-title":"Pigment Cell Melanoma Res"},{"issue":"19","key":"3114_CR26","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175","journal-title":"J Clin Oncol"},{"issue":"7","key":"3114_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58(7):835\u2013857","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3114_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3114_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s40425-018-0465-0","volume":"6","author":"S Bantia","year":"2018","unstructured":"Bantia S, Choradia N (2018) Treatment duration with immune-based therapies in Cancer: an enigma. J Immunother Cancer 6(1):143","journal-title":"J Immunother Cancer"},{"key":"3114_CR30","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5:1310\u20131317","journal-title":"JAMA Oncol"},{"issue":"64","key":"3114_CR31","doi-asserted-by":"publisher","first-page":"32298","DOI":"10.18632\/oncotarget.25949","volume":"9","author":"M Niki","year":"2018","unstructured":"Niki M, Nakaya A, Kurata T et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298\u201332304","journal-title":"Oncotarget"},{"key":"3114_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"140","author":"M Giaj Levra","year":"2020","unstructured":"Giaj Levra M, Cott\u00e9 FE, Corre R et al (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer 140:99\u2013106","journal-title":"Lung Cancer"},{"issue":"5","key":"3114_CR33","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","volume":"21","author":"E Gobbini","year":"2020","unstructured":"Gobbini E, Toffart AT, P\u00e9rol M et al (2020) Immune checkpoint inhibitors rechallenge efficacy in non\u2013small-cell lung cancer patients. Clin Lung Cancer 21(5):e497\u2013e510","journal-title":"Clin Lung Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03114-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T14:03:53Z","timestamp":1654956233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03114-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03114-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the ethical standards of the institutional research committee and the latest Declaration of Helsinki. Study ethics approval was obtained on December 9, 2019 (Observational Research Protocol Review Committee), of the Institut Curie, IRB 2215984.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"An information letter was given to each living patient providing him the opportunity to refuse study participation. All individuals agreed to the use of the obtained data for relevant publications.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}